Status:
ACTIVE_NOT_RECRUITING
Rehabilitation of Cognitive Changes in Breast Cancer Survivors
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
MARTELL FOUNDATION
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-69 years
Phase:
NA
Brief Summary
The purpose of this study is to test a memory training program for breast cancer survivors who have problems with memory after receiving chemotherapy. Since breast cancer survivors have been reported ...
Eligibility Criteria
Inclusion
- Note: Any participant who reports tics can be included, however participants will be told tics may increase during the training period.
- Patients
- Female breast cancer survivors who have received adjuvant chemotherapy 1-10 years from the time of recruitment either at MSKCC or elsewhere
- Stage I, II, III breast cancer as noted in pathology reports or by clinician judgement.
- No evidence of disease at time of screening
- Age range 18 years old through \<70 years old
- Must be able speak, read and write English well enough to complete written and verbal assessments and neurocognitive tests. The software was developed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures.
- Must demonstrate cognitive deficiency, which is defined as 1.0 standard deviations below normative data on at least one of the pre-screen phone assessments (WAIS-III Digit Span, Symbol Digit Modalities Test, Controlled Oral Word Association Test, Rey Auditory Verbal Learning Test) or must have 1.0 standard deviations difference from the pre-morbid estimate of cognitive functioning, Wide Range Achievement Test 4: Reading subtest, and one of the pre-screen phone assessment measures.
- Must have basic computer skills such as able to turn on a computer, open the program, login, and use a mouse.
- Participants must have the ability to upload their data via the internet. A study laptop can be loaned out to participants who do not have a computer or the appropriate operating systems.
- Collateral Participant (if such person is available to the participant, not a requirement of the study) Family member or friend (i.e., collateral) identified by a patient who has at least weekly face to face contact with the patient
- Collateral person is at least 18 years of age
- Family member or friend has adequate English fluency for completion of data collection. The surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures.
- Able to provide informed consent
Exclusion
- Patients
- History of neurological disorder with cognitive symptoms (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, seizure disorder) as per self report or as documented in the electronic medical record.
- History of mental retardation, learning disorder bipolar disorder, schizophrenia, substance use disorder(s), or uncontrolled depression as per self report or as documented in the medical record.
- History of Traumatic Brain Injury with \> or = to 30 minutes loss of consciousness or cognitive sequelae as per self report or as documented in the medical record.
- History of Stroke as per self report or as documented in the medical record.
- Prior history or secondary diagnosis of other cancers except for basal cell carcinoma or melanoma treated with surgery only
- History of multiple courses of chemotherapy.
- Evidence of recurrence at time of screening
- A hearing or visual deficit that impairs the ability to use the software.
- Significant cognitive or psychiatric disturbance sufficient, in the investigator's judgment, to preclude providing informed consent.
- Males will be excluded as only a minority of men gets breast cancer. Thus, there would not be enough men to have equivalent groups to statistically control for possible gender effects.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01182506
Start Date
August 1 2010
End Date
August 1 2026
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021